Geron Corporation (GERN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $622.98M
Last updated: Nov 17, 2026 at 11:06 AM ET
Geron Corporation (GERN) Stock Forecast
Analysts expect Geron (GERN) to earn -$0.02 per share in the fiscal year ending Dec 31, 2026, on revenue of $235.32M. Of 5 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.09.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 3 | 60.0% |
| Hold | 1 | 20.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 43.7%.
- Fiscal year ending Dec 31, 2026
- -$0.02
- EPS consensus, revenue $235.32M
- Fiscal year ending Dec 31, 2027
- $0.09
- EPS consensus, revenue $338.08M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.02 | -$0.02 to -$0.02 | 1 | $235.32M | $234.25M to $236.15M | 5 |
| Dec 31, 2027 | $0.09 | $0.09 to $0.09 | 1 | $338.08M | $311.17M to $413.31M | 5 |
Quarterly Estimates
The EPS consensus rises from $0.00 for the quarter ending Dec 31, 2026 to $0.01 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.00 | -$0.01 to $0.02 | 7 | $66.75M | $62.71M to $69.97M | 7 |
| Mar 31, 2027 | $0.01 | $0.01 to $0.01 | 1 | $74.49M | $68.46M to $85.60M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
Frequently Asked Questions About GERN
What is the GERN stock forecast?
Consensus analyst estimates put Geron's EPS at -$0.02 for the fiscal year ending Dec 31, 2026, on revenue of $235.32M. The consensus rating from 5 analysts is Buy.
How do analysts rate GERN stock?
Of 5 analysts covering Geron, 1 rates it Strong Buy, 3 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from GERN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.02, with estimates from -$0.02 to -$0.02 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.09, with estimates from $0.09 to $0.09 from 1 analyst.
What revenue do analysts expect from Geron next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $235.32M, with estimates from $234.25M to $236.15M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $338.08M, with estimates from $311.17M to $413.31M.
How many analysts cover GERN?
5 analysts rate Geron stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
GERN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors